• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Neuropace Inc.

    6/12/25 4:16:43 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email
    8-K
    NeuroPace Inc false 0001528287 0001528287 2025-06-06 2025-06-06
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 6, 2025

     

     

    NEUROPACE, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40337   22-3550230

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    455 N. Bernardo Avenue

    Mountain View, CA

        94043
    (Address of principal executive offices)     (Zip Code)

    (650) 237-2700

    Registrant’s telephone number, including area code

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value per share   NPCE   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On June 6, 2025, NeuroPace, Inc. held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via live webcast. The following proposals were voted upon, and the final voting results with respect to each such proposal are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2025.

    Proposal 1 - Election of Directors. NeuroPace’s stockholders elected each of the following Class I director nominees to hold office until NeuroPace’s 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal. The results of the vote were:

     

    Nominee    For      Withhold      Broker Non-Votes  

    Joel Becker

         19,735,539        120,448        7,730,356  

    Frank Fischer

         14,717,455        5,138,532        7,730,356  

    Proposal 2 - Ratification of Independent Registered Public Accounting Firm. NeuroPace’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as NeuroPace’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the vote were:

     

    For   Against   Abstain   Broker Non-Votes
    27,489,833   90,789   5,721   — 


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        NeuroPace, Inc.
    Dated: June 12, 2025     By:  

    /s/ Rebecca Kuhn

          Rebecca Kuhn
          Chief Financial Officer and Vice President, Finance and Administration,
    Get the next $NPCE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 1,338 shares, decreasing direct ownership by 2% to 78,734 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    12/4/25 4:30:07 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 103,086 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    12/1/25 4:15:11 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.44% to 80,072 units (SEC Form 4)

    4 - NeuroPace Inc (0001528287) (Issuer)

    12/1/25 4:15:06 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    SEC Filings

    View All

    SEC Form 10-Q filed by Neuropace Inc.

    10-Q - NeuroPace Inc (0001528287) (Filer)

    11/4/25 4:22:46 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NeuroPace Inc (0001528287) (Filer)

    11/4/25 4:10:15 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.

    SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)

    8/14/25 6:03:09 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

    -- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive

    12/8/25 8:00:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

    --Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures-- --CY 2026 Outpatient Prospective Payment System (OPPS) Final Rule moves RNS replacement procedures to highest-paying neurostimulator APC-- NeuroPace, Inc. (NASDAQ:NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicare reimbursement updates for the RNS® System under both the CY 2026 OPPS and Medicare PFS final rules. In the CY 2026 Medicare PFS final rule, the Centers for Medicare & Medicaid Services (CMS) significantly increased professional payment for neurosurge

    11/24/25 8:00:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    -- Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth -- -- Increased full-year 2025 revenue guidance to between $97 million and $98 million and gross margin guidance to between 76% and 77% -- -- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Financial Highlights Total revenue of $27.4 million, representing growth of 30% compared to the thir

    11/4/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on NeuroPace with a new price target

    H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

    5/28/25 9:08:28 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on NeuroPace with a new price target

    UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

    1/21/25 8:23:18 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

    3/14/24 8:11:10 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroPace Announces Strategic CFO Transition

    Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan

    6/24/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Continues to Strengthen Management Team

    MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

    10/16/24 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Strengthens Management Team with Two Key Appointments

    Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

    9/4/24 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Financials

    Live finance-specific insights

    View All

    NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    -- Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth -- -- Increased full-year 2025 revenue guidance to between $97 million and $98 million and gross margin guidance to between 76% and 77% -- -- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Financial Highlights Total revenue of $27.4 million, representing growth of 30% compared to the thir

    11/4/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

    NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event at https://events.q4inc.com/attendee/831496029. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The

    10/22/25 8:00:00 AM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    -- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Second Quarter

    8/12/25 4:05:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 6:30:12 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    11/14/24 3:36:16 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

    SC 13G/A - NeuroPace Inc (0001528287) (Subject)

    10/3/24 4:46:48 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care